GlassScriptPhysician profile
Jeffrey D Reichard
NPI 1326045329
$64,700.78
in general payments reported to CMS, 2019-2025
27 companies · $6,981 in 2025
The $6,981 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $4,112 · 2021: $998 · 2022: $8,599 · 2023: $1,880 · 2024: $4,431 · 2025: $6,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,342 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Travel and Lodging: $1,914 · Education: $36.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,341.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Travel and Lodging | $1,913.84 |
| Education | $36.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35,004.64 | 2019-2025 | |
| Boston Scientific Corporation | $21,974.14 | 2019-2025 | Watchman Access System, Watchman Flx |
| Janssen Pharmaceuticals, INC | $1,643.31 | 2019-2024 | Xarelto |
| Amgen INC. | $1,221.77 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.26 | 2019-2025 | Jardiance |
| Pfizer INC. | $607.77 | 2019-2025 | |
| Amarin Pharma, INC. | $536.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $436.65 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $390.73 | 2019-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $300.20 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $249.70 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $209.41 | 2025 | Sapien 3 Ultra Resilia |
| Regeneron Healthcare Solutions, INC. | $193.03 | 2019-2023 | Evkeeza |
| Esperion Therapeutics, INC. | $190.34 | 2020-2025 | Nexletol |
| Abbott Laboratories | $157.81 | 2021-2023 | Mitraclip |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $150.35 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $148.55 | 2021-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $115.22 | 2019-2020 | |
| Medtronic Vascular, INC. | $101.12 | 2019 | |
| Novo Nordisk INC | $72.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $33.20 | 2024 | Arcalyst |
| Lundbeck LLC | $29.07 | 2019-2020 | |
| Octapharma USA, INC. | $26.11 | 2025 | Fibryga |
| Gilead Sciences, INC. | $15.72 | 2019 | |
| Scpharmaceuticals INC. | $15.34 | 2023 | |
| Bridgebio Pharma, INC. | $14.84 | 2025 | Attruby |
| Nalpropion Pharmaceuticals LLC | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Reichard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.